[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580580":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":42,"locations":47,"responsibleParty":77,"collaborators":79,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":26,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":50,"whyStopped":26,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Arm","EXPERIMENTAL","Patients receive propranolol + etodolac (active treatment)",[13],"Drug: Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Arm","PLACEBO_COMPARATOR","Patients receive matching placebo for both drugs",[19],"Drug: Placebo (Matching for Propranolol & Etodolac)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)","\\- Intervention Arm: Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor). Name: Propranolol (slow-Release) and Etodolac.\n\nPropranolol Dosage Schedule:\n\n5 days pre-surgery: 20mg twice daily (BID), Day of surgery: 80mg BID,\n\n1-week Post-surgery: 40mg BID, week 2-11 post-surgery: 20mg BID.\n\nEtodolac Dosage Schedule:\n\n5 days pre-surgery until 3 weeks post-surgery: 400mg BID.\n\nAdministration Route: Oral.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo (Matching for Propranolol & Etodolac)","\\- Placebo Arm: Placebo (Matching for Propranolol \\& Etodolac). Inert placebo tablets matching propranolol and etodolac in appearance and dosing schedule. Administration Route: Oral.",[15],[32,36,39],{"name":33,"affiliation":34,"role":35},"Nadav Michaan, Prof.","Tel Aviv Sourasky Medical Center (Ichilov Hospital)","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":38,"role":35},"Anna Blecher, Dr.","The Chaim Sheba Medical Center (Tel Hashomer)",{"name":40,"affiliation":41,"role":35},"Shamgar Ben-Eliyahu, Prof.","Tel Aviv University",[43],{"name":40,"role":44,"phone":45,"phoneExt":26,"email":46},"CONTACT","972-3-6407266","shamgar@tauex.tau.ac.il",[48,65],{"facility":49,"status":50,"city":51,"state":26,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"The Chaim Sheba Medical Center","RECRUITING","Ramat Gan","5266202","Israel","IL",{"type":56,"coordinates":57},"Point",[58,59],34.81065,32.08227,{"lat":59,"lon":58},[62],{"name":37,"role":44,"phone":63,"phoneExt":26,"email":64},"972-52-9280101","anna.blecher@sheba.health.gov.il",{"facility":34,"status":50,"city":66,"state":26,"zip":67,"country":53,"countryCode":54,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Tel Aviv","6997801",{"type":56,"coordinates":69},[70,71],34.78057,32.08088,{"lat":71,"lon":70},[74],{"name":33,"role":44,"phone":75,"phoneExt":26,"email":76},"972-52-7360283","nadavm@tlvmc.gov.il",{"type":78,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[80,83],{"name":81,"class":82},"National Cancer Institute (NCI)","NIH",{"name":49,"class":84},"OTHER","100580580","phase-2-inhibiting-beta-adrenergic-and-cox-2-signaling-during-the-perioperative-period-to-reduce-ovarian-cancer-progression-100580580",false,"NCT06839144","Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression","Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression: A Randomized Placebo-Controlled Clinical Trial","OC-POP-PT","Inclusion Criteria:\n\n* Age 20-85\n* ASA score 1-3 or ECOG Performance Status of 0 to 2\n* Patients with a suspected high-grade ovarian epithelial cancer based on imaging, clinical examination, CA125, and\u002For tumor biopsy\n* Patients planned for surgery for primary surgery, or interval debulking surgery for ovarian cancer\n* Signed informed consent form\n* Willing and able to comply with study procedures (physically and mentally)\n\nExclusion Criteria:\n\n* Patients who participate in another interventional study\n* Patients with known allergy to one or more of the study medications, or to any medication from the non-steroidal anti-inflammatory drug group or beta-blockers family\n* Patients treated chronically with any type of a beta-adrenergic blocker or a COX inhibitor, except use of Aspirin, which will be discontinued at least 7 days prior to surgery, and until 3 weeks post-surgery\n* Patients currently suffering from asthma (אסתמה פעילה בלבד), or required hospital admission or change in medical treatment for asthma within the past year\n* Patients with active peptic disease\n* Patients with a history of CVA\u002FTIA\n* Recent (within the last 5 years) or concurrent malignancies, with the exception of adequately treated in-situ carcinoma of the cervix or basal-cell carcinoma of the skin\n* Patients with renal failure, measured by creatinine level \\>1.5\n* Patients with significant liver dysfunction (known cirrhosis, Bilirubin level\\>2)\n* Patients with significant heart failure (NYHA functional class 3 or Higher)\n* Patients with bradycardia (heart rate of 50 or less) or second- or third-degree AV block\n* Patients with right-sided heart failure owing to pulmonary hypertension\n* Patients with chronic Digoxin treatment\n* Patients with Printzmetal's angina\n* Patients with significant diagnosed cardiomegaly\n* Patients suffering from sick sinus syndrome\n* Patients with peripheral vascular disease\n* Patients with current (unresected) pheochromocytoma\n* Pregnant women\n* Patients who are treated with immunosuppressive medications, including chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial drug\n* Patients with Immunodeficiency Disorders","FEMALE","20 Years","85 Years",{"count":97,"type":98},60,"ESTIMATED","INTERVENTIONAL",[101],"PHASE2","This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.",[104,105],"Ovarian Cancer","Ovarian Cancer Metastatic Recurrent",[104,107,108,109,110,111,112,113,114,115],"Perioperative Intervention","Beta-Blockers","Propranolol","COX-2 Inhibitors","Etodolac","Psychoneuroimmunology","Stress and Cancer","Randomized Controlled Trial (RCT)","Biomarker Analysis","2025-07-08",{"date":118,"type":119},"2025-07-11","ACTUAL",{"date":121,"type":119},"2025-03-12",{"date":123,"type":98},"2026-08-31",{"name":5,"class":6},2]